SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to reduce cardiovascular risk and mortality in patients with type 2 diabetes mellitus (T2D) and established cardiovascular disease, yet remain underutilized in clinical practice.